CAMBRIDGE, Mass., Sept. 24,
2024 /PRNewswire/ -- NeuroSense Therapeutics
Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing
treatments for severe neurodegenerative diseases, today announced
that it has received notice from The Nasdaq Stock Market LLC
("Nasdaq") informing the Company that it has regained compliance
with the minimum bid price requirement under Nasdaq Listing Rule
5550(a)(2) (the "Rule") for continued listing.
To regain compliance with the Rule, the Company's ordinary
shares were required to maintain a minimum closing bid price of
$1.00 or more for at least 10
consecutive business days, which was achieved on September 20, 2024. Therefore, the Nasdaq Listing
Qualifications Staff considers the prior bid price deficiency
matter now closed.
NeuroSense's CEO, Alon Ben-Noon said, " We are pleased
to have regained compliance with Nasdaq's minimum bid price
requirement, an important step that reflects our commitment to
advancing PrimeC. With the positive momentum following our Phase
2b trial results, we are looking
forward to initiating the Phase 3 trial in the US and continuing
our discussions with potential partners."
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
For additional information, we invite you to visit
our website and follow us on LinkedIn,
YouTube and X. Information that may be important to
investors may be routinely posted on our website and these social
media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding initiating the Phase 3
trial for PrimeC in the US. Further, certain
forward-looking statements are based on assumptions as to future
events that may not prove to be accurate. The future events and
trends may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward looking
statements. These risks include unexpected R&D costs or
operating expenses, a delay in the reporting of additional results
from PARADIGM clinical trial or a delay
in initiating the Phase 3 trial for
PrimeC in the US, the timing of expected regulatory and business
milestones, risks associated with meeting with the FDA to determine
the best path forward following the results from PARADIGM clinical
trial, including a delay in any such meeting; the potential for
PrimeC to safely and effectively target ALS; preclinical and
clinical data for PrimeC; the uncertainty regarding outcomes and
the timing of current and future clinical trials; timing for
reporting data; the development and commercial potential of any
product candidates of NeuroSense; and other risks and
uncertainties set forth in NeuroSense's filings with the Securities
and Exchange Commission (SEC). You should not rely on these
statements as representing our views in the future. More
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Annual Report
on Form 20-F filed with the Securities and Exchange Commission on
March 22, 2023. Forward-looking
statements contained in this announcement are made as of this date,
and NeuroSense undertakes no duty to update such information except
as required under applicable law.
Logo:
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule-302257073.html
SOURCE NeuroSense
